Full-Time

Senior ML Engineer

Agentic AI & Scientific Systems

Updated on 8/24/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's

Category
Data & Analytics (1)
Required Skills
LLM
Python
Distributed Systems
Machine Learning
RAG
LangGraph
LangChain

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A Bachelor of Science or Master of Science degree in Computer Science, Engineering, Computational Biology, Bioinformatics, or a related field is required.
  • Strong hands-on experience developing artificial intelligence and machine learning solutions is required.
  • Expertise in Python and modern artificial intelligence and machine learning development frameworks is required.
  • Experience designing and implementing production-quality software systems is required.
  • Strong engineering background in artificial intelligence and machine learning systems is required.
  • Hands-on experience with large language models, agent frameworks, retrieval-augmented generation, vector databases, API-driven architectures, and Python-based artificial intelligence and machine learning ecosystems is required.
  • Understanding of the machine learning lifecycle and evaluation, scientific computing workflows, distributed systems and scalable architectures, and knowledge graph concepts and graph-based artificial intelligence approaches is required.
  • Ability to operate effectively in collaborative, cross-functional scientific environments is required.
Responsibilities
  • Design and implement agent-based systems that support complex scientific workflows.
  • Develop tool-calling and tool-orchestration capabilities, multi-step reasoning workflows, retrieval-augmented generation, knowledge-grounded artificial intelligence systems, human-in-the-loop decision workflows, and multi-agent collaboration patterns.
  • Build reusable components for agent orchestration, context management, memory and state handling, workflow planning and execution, and scientific tool integration.
  • Evaluate emerging agent frameworks and contribute to standards and best practices across projects.
  • Integrate foundation models and scientific artificial intelligence models into end-to-end workflows, including protein language models, structure prediction models, biological foundation models, knowledge graph-based systems, and predictive machine learning models.
  • Develop reusable application programming interfaces, services, and interfaces that allow artificial intelligence agents and applications to consume scientific models and computational tools.
  • Collaborate with scientific domain experts to identify appropriate modeling approaches and evaluate solution effectiveness.
  • Design and implement knowledge-driven artificial intelligence systems that connect large language models and agents with enterprise and scientific data.
  • Develop solutions using retrieval-augmented generation, vector databases, knowledge graphs, Graph-RAG architectures, and scientific literature and domain knowledge repositories.
  • Ensure artificial intelligence systems leverage authoritative knowledge sources and support traceability and explainability.
  • Develop end-to-end workflows combining data ingestion and preparation, knowledge retrieval, model inference, agent orchestration, and scientific analysis.
  • Create reusable workflow patterns applicable across multiple scientific domains and projects.
  • Contribute to architectural decisions regarding workflow design, model integration, and artificial intelligence system composition.
  • Develop evaluation frameworks for artificial intelligence systems, agents, and workflows.
  • Establish approaches for measuring accuracy, reliability, scientific relevance, hallucination rates, workflow effectiveness, user adoption, and impact.
  • Support responsible artificial intelligence practices, including transparency, traceability, and governance requirements.
  • Partner with artificial intelligence domain leads, scientists and researchers, data engineering teams, platform engineering teams, and enterprise artificial intelligence platform teams.
  • Translate scientific requirements into technical solutions and provide guidance on artificial intelligence capabilities, limitations, and implementation approaches.
  • Contribute to technical design reviews and mentor junior team members where appropriate.
  • Make implementation decisions regarding agent architectures, workflow composition, knowledge retrieval strategies, model integration approaches, and evaluation methodologies.
  • Influence broader architectural direction through technical expertise and collaboration with senior technical leaders.
Desired Qualifications
  • Experience with large language models, agentic artificial intelligence systems, and workflow orchestration.
  • Experience with retrieval-augmented generation, vector databases, and knowledge-driven artificial intelligence architectures.
  • Experience integrating scientific or domain-specific artificial intelligence models.
  • Familiarity with biological, biomedical, or life sciences data.
  • Experience with cloud artificial intelligence platforms such as AWS Bedrock, SageMaker, or Azure AI.
  • Familiarity with knowledge graphs, Graph-RAG, or scientific knowledge systems.
  • Experience working closely with researchers and domain experts.
  • Five to nine years of experience for candidates with a Bachelor's degree.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
  • Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
  • Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.

What critics are saying

  • FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
  • Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.

What makes Amgen unique

  • Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
  • MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
  • Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.